Feb 5 (Reuters) - Drug distributor McKesson MCK.N missed estimates for third-quarter revenue on Wednesday, hurt by less-than-expected sales in its U.S. pharmaceutical segment, which includes branded and specialty drugs.
Shares of the Texas-headquartered company fell 3% in extended trading.
Drug distributors in the United States are expanding their presence in the market for specialty medicines, which treat complex conditions such as rheumatoid arthritis and cancer, due to their high profit margins.
Mckesson's results are in contrast with peer Cardinal COR.N, which raised its 2025 profit forecast and beat quarterly earnings estimates last week, on strength in its pharmaceuticals unit.
The company reported third-quarter revenue of $95.29 billion, missing analysts' average estimate of $96.08 billion, according to data compiled by LSEG.
The drug distributor's U.S. pharmaceutical unit — its largest segment by revenue — recorded sales of $87.11 billion. While that was 19% higher than the year earlier, it missed analysts' estimate of $88.92 billion.
On an adjusted basis, McKesson earned $8.03 per share, compared with the estimates of $7.99 per share.
Mckesson revised its profit forecast range to $32.55 to $32.95 per share for 2025, compared with its previous projection of $32.40 to $33.00 per share.
(Reporting by Christy Santhosh in Bengaluru; Editing by Shilpi Majumdar)
((Christy.Santhosh@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。